With bb2121, Is CAR T-Cell Therapy Ready for Myeloma?

Skip Nav Destination

December 30, 2021

Content License:Private

Noopur Raje, MD, discusses updated data from a phase I trial of the second-generation, anti-BCMA CAR T-cell therapy for relapsed/refractory myeloma.

With bb2121, Is CAR T-Cell Therapy Ready for Myeloma?

ASH Publications

American Society of Hematology

With bb2121, Is CAR T-Cell Therapy Ready for Myeloma?

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only